The Four-Hit Theory in IgA Nephropathy
The four-hit hypothesis is the currently accepted pathogenic model for IgA nephropathy, describing a sequential cascade of immunologic events that culminates in glomerular injury and progressive kidney disease 1, 2.
The Four Sequential Hits
The pathogenesis unfolds through four distinct, sequential steps:
Hit 1: Production of Galactose-Deficient IgA1
The initial abnormality involves increased circulating levels of IgA1 antibodies with aberrant O-glycosylation—specifically, IgA1 molecules deficient in galactose on their hinge-region O-glycans (galactose-deficient IgA1, or Gd-IgA1) 2. This glycosylation defect appears to originate from mucosal immune responses, often triggered by infections in the respiratory tract, intestines, or other mucosal surfaces 3, 4.
Hit 2: Formation of Autoantibodies
The galactose-deficient IgA1 molecules are recognized as autoantigens, triggering production of unique IgG (and sometimes IgA) autoantibodies that specifically target the abnormally glycosylated hinge region 2. This represents an autoimmune response where the body's immune system attacks its own aberrantly glycosylated proteins.
Hit 3: Formation of Immune Complexes
The autoantibodies bind to galactose-deficient IgA1, forming circulating IgA1-IgG immune complexes (IgA-ICs) 2, 5. These pathogenic immune complexes circulate in the bloodstream before depositing in target organs.
Hit 4: Glomerular Deposition and Injury
The circulating immune complexes deposit in the glomerular mesangium, where they activate mesangial cells and trigger complement activation (particularly through alternative and lectin pathways), leading to glomerular inflammation, proliferation, and ultimately progressive kidney injury 3, 4, 2. The kidneys act as "innocent bystanders" damaged by deposition of these circulating immune complexes 2.
Clinical and Therapeutic Implications
This four-hit model directly informs the development of targeted therapies, with different agents addressing specific steps in the pathogenic cascade 1, 6:
- Hit 1 interventions: Mucosal immunomodulators like targeted-release budesonide aim to reduce production of galactose-deficient IgA1 at mucosal sites 5
- Hit 2-3 interventions: B-cell targeted agents (anti-APRIL/BAFF inhibitors like telitacicept and atacicept) prevent autoantibody formation and immune complex generation 3, 4
- Hit 4 interventions: Complement inhibitors (like iptacopan and narsoplimab) block the downstream inflammatory cascade triggered by mesangial immune complex deposition 3, 5
Important Caveats
While the four-hit theory remains foundational, recent evidence suggests it may be incomplete. The "spiral hypothesis" has been proposed as a more dynamic model that better captures IgAN's recurrent, self-amplifying nature and explains why the disease demonstrates chronicity requiring sustained maintenance therapy rather than cure 6. The four-hit model, while mechanistically accurate, may oversimplify the cyclical immune-injury cascades that perpetuate disease progression.
Genetic studies have identified multiple susceptibility genes that influence each of the four hits, highlighting the complex genetic architecture underlying this pathogenic cascade 4. Additionally, the role of the gut microbiota in modulating mucosal immunity and IgA production adds another layer of complexity to the initial hit 4.